

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Hiroyuki SAITO et al.

Title: PREVENTION AND TREATMENT  
OF BLOOD COAGULATION-  
RELATED DISEASES

Appl. No.: Unassigned

Filing Date: 03/29/2002

Examiner: Unassigned

Art Unit: Unassigned

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Commissioner for Patents  
Box PCT  
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the date of entry of the national stage as set forth in 37 CFR §1.491.

**RELEVANCE OF EACH DOCUMENT**

Any document listed on the attached PTO/SB/08 was cited as being relevant during the prosecution of the corresponding International application. Copies of the documents are not being provided since copies should have been provided directly by WIPO under an exchange program between the PTO, the EPO and the JPO.

A copy of the International Search Report is attached setting forth the portion of each document considered relevant by the examiner. English-language translations of the foreign-language documents have not been provided. The absence of a translation or an English-language counterpart document does not relieve the PTO from its duty to consider any submitted document (37 CFR § 1.98 and MPEP § 609).

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP § 609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

By



Harold C. Wegner  
Attorney for Applicants  
Registration No. 25,258

Date March 29, 2002

FOLEY & LARDNER  
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5571

Facsimile: (202) 672-5399

- Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

JC13 Rec'd PCT/PTO 29 MAR 2002

Substitute for form 1449B/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Application Number	Unassigned	
			Filing Date	03/29/2002	
Date Submitted: March 29, 2002			First Name of Inventor	Hiroyuki SAITO	
			Group Art Unit	Unassigned	
(use as many sheets as necessary)			Examiner Name	Unassigned	
			Attorney Docket Number	053466-0325	
Sheet	1	of	1		

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	A1	5,346,991		ROY et al.	09/13/1994	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	A2	IL	85411		GENENTECH, INC.	07/31/1998		
	A3	WO	88/09817	✓	NEMERSON et al.	12/15/1988		
	A4	WO	88/07543	✓	EDGINGTON et al.	10/06/1988		

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A5	RANDOLPH, G. et al. "Role of Tissue Factor in Adhesion of Mononuclear Phagocytes to and Trafficking Through Endothelium In Vitro," <i>Blood</i> (December 1, 1998), Vol. 92, No. 11, pp. 4167-4177.	✓
	A6	GIESEN, P. et al. "Blood-borne tissue factor: Another view of thrombosis," <i>Proc. Natl. Acad. Sci.</i> (March 1999), Vol. 96, pp. 2311-2315.	✓
	A7	NAKAYAMA, T. et al., (1999) Vol. 39, No. 4, 298-302.	✓
	A8	DRAKE, T. et al. "Functional Tissue Factor Is Entirely Cell Surface Expressed on Lipopolysaccharide-stimulated Human Blood Monocytes and a Constitutively Tissue Factor-producing Neoplastic Cell Line," <i>The Journal of Cell Biology</i> (July 1989), Vol. 109, pp. 389-395, The Rockefeller University Press.	✓
	A9	RAN, S. et al. "Infarction of Solid Hodgkin's Tumors in Mice by Antibody-directed Targeting of Tissue Factor to Tumor Vasculature," <i>Cancer Research</i> (October 15, 1998), pp. 4646-4653.	✓
	A10	BELLAMY, W. et al. "Development of an orthotopic SCID mouse-human tumor xenograft model displaying the multidrug-resistant phenotype," <i>Cancer Chemother Pharmacol</i> (1996), Vol. 37, pp. 305-316.	✓
	A11	HUANG, X. et al. "Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature," <i>Science</i> (24 January 1997), Vol. 275, pp. 547-550.	✓
	A12	MORRISSEY, J. "Molecular Cloning of the cDNA for Tissue Factor, the Cellular Receptor for the Initiation of the Coagulation Protease Cascade," <i>Cell</i> (July 3, 1987), Vol. 50, pp. 129-135, Cell Press.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.